Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.

CONCLUSION: The newly developed GC-SVM classifier was a powerful predictor of OS and DFS. Moreover, the GC-SVM classifier could predict which patients with stage II and III GC benefit from adjuvant chemotherapy. PMID: 30042208 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30042208?dopt=Abstract

Source: Clinical Cancer Research - July 24, 2018 Category: Cancer & Oncology Authors: Jiang Y, Xie J, Han Z, Liu W, Xi S, Huang L, Huang W, Lin T, Zhao LY, Hu YF, Yu J, Zhang Q, Li T, Cai SR, Li G Tags: Clin Cancer Res Source Type: research